6533b851fe1ef96bd12a9065
RESEARCH PRODUCT
Editorial: stepwise risk stratification for both F3 and F4 in NAFLD patients-authors' reply.
Jörn M. SchattenbergChristian Labenzsubject
Liver Cirrhosismedicine.medical_specialtyHepatologybusiness.industryGastroenterologyFibrosisRisk Assessment03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver Disease030220 oncology & carcinogenesisGermanyRisk stratificationmedicineHumans030211 gastroenterology & hepatologyPharmacology (medical)Intensive care medicinebusinessyear | journal | country | edition | language |
---|---|---|---|---|
2018-11-30 | Alimentary pharmacologytherapeutics |